Table 1 Clinical characteristics and laboratory data of 60 children with transfusion-dependent beta-thalassemia major (TDT)
Characteristics of the studied children | Total number = 60 |
|---|---|
Age (years)¶ | 5–15 (13.23 ± 3.01) |
Sex | |
Males/females | 38 (63.3%)/22 (36.7%) |
Wt. (kg)¶ | 18–48 (29.73 ± 4.76) |
Height (cm)¶ | 110–160 (126.60 ± 12.4) |
Duration of the disease (years) | 4 -15 (5.88 ± 3.42) |
Iron chelating agents | |
Regular/irregular | 32 (53.3%)/28 (46.7%) |
Type of chelation therapy | |
Deferoxamine monotherapy (SC, IV) | 10 (16.6%) |
Deferasirox monotherapy (Oral) | 25 (41.7%) |
Deferiprone monotherapy (Oral) | 6 (10%) |
Deferoxamine (SC,IV) and deferasirox (Oral) | 19 (31.7%) |
Splenectomy | |
Done/not done | 34/60 (56.6%)/ 26/60 (43.4%) |
Hb level (gm/dl)¶ | 7–10.5 (9.01 ± 1.2) |
Serum iron (mcg/dl)¶ | 650–1200 (803.68 ± 261.36) |
Serum ferritin (ng/ ml)¶ | 1900–6000 (2639.47 ± 835.06) |